Epigenetic inhibition of hedgehog pathway signalling in tumours
Nature Medicine
2014년6월30일
A method to overcome one type of drug resistance in some instances of brain or skin cancer in mice, by using an epigenetic inhibitor of the hedgehog signalling pathway, is reported online in Nature Medicine. This offers a new avenue for therapy where present drugs targeting the hedgehog signalling pathway, which drives tumour growth and development, have been hindered by emerging drug resistance.
The hedgehog signalling pathway leads to activation of the Gli proteins which in turn contribute to the signalling cascade that promotes tumour growth and development. To block hedgehog signalling, Yoon-Jae Cho and colleagues targeted the BET protein family of chromatin regulators-molecular complexes that regulate gene expression.
They found that inhibiting BET proteins with a small molecule, JQ1, could decrease expression of Gli proteins. JQ1 impaired the growth of tumours in mice that were sensitive or resistant to hedgehog pathway inhibitor drugs, suggesting that targeting epigenetic regulators of gene expression, such as the BET proteins, downstream in the pathway could be an effective adjunctive treatment for these tumours.
doi: 10.1038/nm.3613
리서치 하이라이트
-
10월14일
Astronomy: How methane frost forms on Pluto’s mountain topsNature Communications
-
10월9일
Sport science: Olympic swimming podium places may be decided by time of dayScientific Reports
-
9월9일
Ecology: Fast-growing trees die young and could affect carbon storageNature Communications
-
9월9일
Epidemiology: US COVID-19 cases may be substantially underestimatedNature Communications
-
9월3일
Physics: Turning buoyancy on its headNature
-
8월19일
Environment: Atlantic Ocean contains more plastic than previously thoughtNature Communications
